grant
Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections
Organization WEST VIRGINIA UNIVERSITYLocation MORGANTOWN, UNITED STATESPosted 1 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY2025Active ImmunizationActive vaccinationAddressAffectAgeAntibiotic AgentsAntibiotic DrugsAntibioticsAntibodiesAntibody TherapyAntimicrobial ResistanceAntiseraBacteriaBacterial Antibiotic ResistanceBindingBlood SerumCell BodyCell Membrane PermeabilityCellsCellular MembraneCenters for Disease ControlCenters for Disease Control and PreventionCenters for Disease Control and Prevention (U.S.)Cessation of lifeClassificationClinicalClinical Treatment MoabCommunicable DiseasesComplementComplement ProteinsDataDeathDevelopmentEndotoxinsFutureGenerationsGoalsHumanHumoral ImmunitiesImmuneImmune SeraImmune mediated therapyImmune systemImmunesImmunocompromisedImmunocompromised HostImmunocompromised PatientImmunologically Directed TherapyImmunosuppressed HostImmunotherapyIn VitroIndividualInfectionInfectious DiseasesInfectious DisorderKnowledgeLaboratoriesLipopolysaccharidesMDR P aeruginosaMDR P. aeruginosaMDR Pseudomonas aeruginosaMDR organismMDR pathogenMembraneMiceMice MammalsMicrobial BiofilmsMiscellaneous AntibioticMissionModern ManMolecular InteractionMonoclonal AntibodiesMulti-Drug ResistanceMultidrug ResistanceMultiple Anti-bacterial Drug ResistanceMultiple Anti-bacterial Drug ResistantMultiple Bacterial Drug ResistanceMultiple Drug ResistanceMultiple Drug ResistantMurineMusNational Institutes of HealthP aeruginosaP. aeruginosaP. aeruginosa infectionPassive ImmunizationPatientsPneumoniaPre-Clinical ModelPreclinical ModelsPreclinical dataPreventionProductionPseudomonas aeruginosaPseudomonas aeruginosa infectionPseudomonas aeruginosa multi drug resistancePseudomonas pyocyaneaPublic HealthResearchResistanceResistance to Multi-drugResistance to MultidrugResistance to Multiple Anti-bacterial DrugResistance to Multiple DrugResistant to Multiple Anti-bacterial DrugResistant to Multiple DrugResistant to multi-drugResistant to multidrugRoleRunningSepsisSerotypingSerumSurfaceSystematicsTestingTherapeuticTherapeutic AgentsTherapeutic antibodiesUnited States Centers for Disease ControlUnited States Centers for Disease Control and PreventionUnited States National Institutes of HealthVaccinatedVaccinationVariantVariationWhole Cell VaccineWorkWorld Health Organizationagesanti-microbial resistantanti-microbial resistant infectionantibiotic resistant bacteriaantibody based therapiesantibody treatmentantibody-based immunityantibody-based therapeuticsantibody-based treatmentantimicrobial resistant infectionbacterial antibiotic resistantbacterial resistance to antibioticbiofilmblood infectionbloodstream infectionclinical applicabilityclinical applicationcomplementationcytokine release syndromecytokine stormdeath due to sepsisdeath related to sepsisdetermine efficacydevelopmentalefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyfightinghealth care associated infectionsimmune serumimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunosuppressed patientimprovedin vivoindividuals with sepsisinfected with P. aeruginosainfected with Pseudomonas aeruginosainfection in the bloodinfection of the bloodinterestmAbsmembrane permeabilitymembrane structuremonoclonal Absmortality associated with sepsismortality in sepsismulti-drug resistantmulti-drug resistant P. aeruginosamulti-drug resistant Pseudomonas aeruginosamulti-drug resistant bacteriamulti-drug resistant organismmulti-drug resistant pathogenmultidrug resistantmultidrug resistant P. aeruginosamultidrug resistant bacteriamultidrug resistant organismmultidrug resistant pathogenmultidrug-resistant P. aeruginosamultidrug-resistant Pseudomonas aeruginosamultiple drug resistant organismmultiple drug resistant pathogennew approachesnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel approachesnovel strategiesnovel strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachpassive vaccinationpathogenpatients with sepsispeople with sepsispreclinical findingspreclinical informationpreventpreventingprophylacticresistance to anti-microbialresistantresistant to antimicrobialresponsesepsis associated deathsepsis associated mortalitysepsis caused deathssepsis deathsepsis groupssepsis induced deathsepsis induced mortalitysepsis lethalitysepsis mortalitysepsis patientssepsis populationsepsis related deathssepsis related mortalitysepsis subjectsseptic deathseptic groupseptic individualsseptic mortalityseptic patientsseptic peopleseptic populationseptic subjectsocial rolestandard of caresubjects with sepsistherapeutic evaluationtherapeutic testingvaccine antibodiesvaccine induced antibodiesvaccine-induced antibodies
Description preview
SUMMARY
The goal of this proposal is to develop therapeutic antibodies for the treatment of multidrug resistant (MDR) P.
aeruginosa infections, with an emphasis on sepsis. With the rise in antimicrobial resistance around the world we
are running out of therapeutic options against MDR P. aeruginosa. Our laboratory has identified a potential…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click